Deadline: 31-May-2026
The DayOne Accelerator is inviting applications from healthtech and techbio startups developing solutions that support pharmaceutical research and development (R&D). This three-month hybrid accelerator based in Basel, Switzerland is equity-free and fee-free, open to global startups from pre-seed to Series A, and offers up to CHF 1,000 in travel support for the initial bootcamp, with possible post-accelerator support of up to CHF 50,000 in non-dilutive funding, additional tailored support, and office space.
What is the DayOne Accelerator?
The DayOne Accelerator is a three-month hybrid programme designed to help high-potential healthtech and techbio startups grow by building solutions at the intersection of:
- Healthcare technology
- Pharmaceutical research and development (R&D)
Based in Basel, Switzerland, the programme supports startups in refining their market positioning, strengthening their value proposition for pharma, and building strategic industry connections.
It is especially aimed at ventures that want to collaborate or partner with pharmaceutical companies.
Programme Format
Duration and Structure
- Duration: 3 months
- Format: Hybrid
- Location: Basel, Switzerland
Basel is positioned as one of Europe’s leading life sciences innovation hubs, making the programme highly relevant for startups seeking pharma ecosystem access.
Focus Areas
The accelerator is looking for healthtech and techbio solutions that enable pharma R&D.
Examples of Relevant Solutions
Eligible and relevant startup solutions may include:
- AI-aided drug discovery
- Digital biomarkers
- Imaging biomarkers
- Diagnostics
- Clinical trial protocol optimization
- Patient screening
- Patient stratification
- Decentralized clinical trials
- Remote monitoring solutions
The programme also emphasizes:
- Value proposition development
- Industry collaboration
- Accelerated business growth
Who Can Apply?
The programme targets:
- Founders
- Startup teams
Working in:
- Healthtech
- Techbio
Ideal Applicant Profile
Applicants should be building solutions that are relevant to:
- Pharmaceutical R&D
- Clinical development
- Trial optimization
- Biomarker or diagnostic innovation
- Drug discovery enablement
Startup Stage Eligibility
The accelerator is open to startups that are:
- Pre-seed
- Seed
- Series A
Funding Threshold
Applicants must have raised:
- Less than USD 10 million in dilutive funding
This makes the programme particularly suitable for early-stage but venture-ready startups.
Global Eligibility
Geographic Scope
- Applicants from any country are eligible
Company Registration Flexibility
The programme is open to:
- Formally registered startups
- Individuals or teams who have not yet formally registered a company
This is a strong advantage for very early-stage founders still validating or structuring their venture.
Financial Support During the Programme
Travel Support for Initial Bootcamp
Selected ventures may receive:
- Up to CHF 1,000
This funding can help cover:
- Travel costs
- Accommodation costs
Important Note
Travel support is:
- Based on country of origin
- Provided at the discretion of Basel Area Business & Innovation
So it is not guaranteed for all participants.
Key Benefits of the DayOne Accelerator
Selected startups gain access to:
- Direct connections to pharma industry experts
- Access to key players in the Basel life sciences ecosystem
- Hands-on mentorship
- Support to refine a pharma-specific value proposition
- Opportunities to engage with global pharmaceutical leaders
- Exposure to one of Europe’s top life sciences hubs
Post-Accelerator Support
High-performing or selected startups may also access additional support after the accelerator.
Potential Post-Programme Benefits
- Up to CHF 50,000 in non-dilutive funding
- Personalized support of equal value
- Up to 12 months of office space
This post-accelerator package can significantly strengthen a startup’s ability to continue scaling after the programme ends.
Cost and Equity Terms
One of the strongest features of the programme is that it is:
- Equity-free
- Fee-free
This means:
- No ownership stake is taken
- No programme fee is charged
Startups can therefore participate while maintaining independence.
What Makes a Strong Application?
A strong application should clearly demonstrate:
- Strong fit at the intersection of healthtech / techbio and pharma R&D
- A compelling solution to a real industry pain point
- Clear potential for pharma collaboration or partnership
- A well-defined or emerging value proposition
- Strong technical or scientific credibility
- Early traction, pilots, validation, or strategic insight (if available)
- Ability to benefit from the Basel pharma ecosystem
- Strong founder-team capability
Application Tips
- Show clear pharma relevance
Make it obvious how your product supports:- Drug discovery
- Clinical trials
- Diagnostics
- Biomarkers
- Patient stratification
- Remote monitoring
- Emphasize industry collaboration potential
The programme is built for startups that want to work with pharmaceutical companies. - Highlight stage fit
Confirm that you are:- Pre-seed to Series A
- Under the USD 10 million dilutive funding cap
- Explain your value proposition clearly
Show why your solution matters specifically in a pharma R&D context, not just general digital health. - Leverage the Basel angle
Demonstrate why access to the Basel life sciences ecosystem could materially accelerate your startup. - Mention if you are not yet incorporated
If applicable, note that the programme still allows unregistered teams, which can work in your favour if your concept is strong.
Common Mistakes to Avoid
Avoid these common errors:
- Presenting a general healthtech startup with weak relevance to pharma R&D
- Failing to explain how pharma companies would use or buy the solution
- Applying above the USD 10 million dilutive funding threshold
- Not showing why the startup is at the right stage for acceleration
- Ignoring the importance of value proposition refinement
- Assuming travel support is guaranteed for all participants
- Treating the programme like a general startup incubator rather than a pharma-facing accelerator
FAQ
1. What is the DayOne Accelerator?
It is a three-month hybrid accelerator in Basel, Switzerland for healthtech and techbio startups building solutions that support pharmaceutical R&D.
2. Who can apply?
The programme is open to:
- Founders
- Startup teams
- Healthtech ventures
- Techbio ventures
From any country.
3. What startup stages are eligible?
Eligible startups should be:
- Pre-seed
- Seed
- Series A
4. Is there a funding cap for applicants?
Yes. Startups must have raised:
- Less than USD 10 million in dilutive funding
5. Do applicants need to have a registered company?
No. The programme is open to:
- Registered companies
- Individuals or teams that have not yet formally registered a company
6. Is the accelerator free?
Yes. The accelerator is:
- Equity-free
- Fee-free
7. Is travel support available?
Yes. Selected ventures may receive:
- Up to CHF 1,000
to help cover travel and accommodation for the initial bootcamp, subject to country of origin and organiser discretion.
8. Is there funding after the accelerator?
Yes. Selected startups may access:
- Up to CHF 50,000 in non-dilutive funding
- Personalized support of equal value
- Up to 12 months of office space
Conclusion
The DayOne Accelerator 2026 is a highly valuable opportunity for healthtech and techbio startups aiming to work closely with the pharmaceutical industry.
With a hybrid Basel-based format, equity-free participation, global eligibility, access to top pharma experts, and potential post-accelerator funding of up to CHF 50,000, the programme is especially attractive for early-stage ventures building solutions in drug discovery, clinical development, diagnostics, and decentralized trials.
For more information, visit Basel Area Business & Innovation.
